Clinical Trial Update: A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren [Phase 2]

View source ↗

Summary

Phase 2 study assessing dystrophin levels in nmDMD patients treated with ataluren has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• ataluren (ataluren)

Snippet

Sponsor: PTC Therapeutics | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: COMPLETED | Results posted: 2022-04-05